Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Multiple Cancer Types

Pediatric Leukemia, Pediatrics
III
Zarnegar-Lumley, Sara
NCT03959085
COGAALL1732

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: